Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):183-90. doi: 10.1097/MPG.0b013e3181a70f21.

Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.

Author information

1
Nationwide Children's Hospital, Columbus, OH 43205, USA. Wallace.Crandall@NationwideChildrens.org

Abstract

OBJECTIVE:

Post hoc analyses evaluated the effect of infliximab upon concurrent perianal Crohn disease (CD) in a subpopulation of 31 patients from REACH, a randomized trial of 112 children with moderately to severely active luminal CD.

MATERIALS AND METHODS:

The Pediatric Crohn Disease Activity Index perirectal subscore was used to assess perianal symptom activity and therapeutic response. Patients with no symptoms or asymptomatic tags received a score of 0; those with "1-2 indolent fistula, scant drainage, no tenderness" received a score of 5; and those with "active fistula, drainage, tenderness or abscess" received a score of 10. Initial perirectal subscores of 10 or 5 decreasing to 0 were considered complete response. Subscores of 10 decreasing to 5 were considered partial response. All patients were followed for efficacy and safety through week 54.

RESULTS:

Twenty-two patients with baseline perianal disease were randomized at week 10 following a 3-dose infliximab induction regimen. At week 2, 40.9% (9/22) of patients with signs and symptoms of perianal disease at baseline attained response (4 partial and 5 complete). At week 54, 72.7% (16/22) of patients with signs and symptoms of perianal disease attained response (1 partial and 15 complete). Nine patients developed perianal signs and symptoms during treatment; 7 had complete response and 2 had no response at week 54. The incidence of adverse events for patients with perianal symptoms at baseline and for those in the overall REACH population was similar (95.7% vs 94.6%).

CONCLUSIONS:

Infliximab rapidly reduced concurrent perianal disease signs and symptoms in this REACH cohort.

PMID:
19561542
DOI:
10.1097/MPG.0b013e3181a70f21
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center